[目的]系统评价刮痧对颈肩痛的治疗效果和安全性,为临床推广刮痧疗法提供循证依据。[方法]应用计算机检索PubMed、EBSco、Web of Science、Cochrane图书馆4个英文数据库以及中国期刊全文数据库(CNKI)、万方科技期刊全文数据库(WanFang)...[目的]系统评价刮痧对颈肩痛的治疗效果和安全性,为临床推广刮痧疗法提供循证依据。[方法]应用计算机检索PubMed、EBSco、Web of Science、Cochrane图书馆4个英文数据库以及中国期刊全文数据库(CNKI)、万方科技期刊全文数据库(WanFang)、中国生物医学网(CBM)3个中文数据库中关于刮痧干预颈肩痛的随机对照试验,对纳入研究的文献进行偏倚风险评价,采用RevMan 5.3软件进行Meta分析。[结果]共纳入11项随机对照试验,涉及1 044例病人。Meta分析结果显示:刮痧疗法可有效地改善颈肩痛疗效[Rr=1.14,95%CI(1.08,1.19),P<0.000 01],提高颈部活动功能[MD=-6.11,95%CI(-10.44,-1.77),P=0.006],但在缓解病人疼痛方面差异无统计学意义[SMD=-1.51,95%CI(-3.06,0.04),P=0.06]。[结论]刮痧治疗颈肩痛安全、有效,但是由于纳入研究的数量和质量均不高,其确切疗效还需要大样本的随机对照试验来验证。展开更多
Thalidomide is an effective drug for the treatment of ankylosing spondylitis but might induce peripheral neuropathy. This major adverse reaction has attracted much concern. The current study aimed to observe the incid...Thalidomide is an effective drug for the treatment of ankylosing spondylitis but might induce peripheral neuropathy. This major adverse reaction has attracted much concern. The current study aimed to observe the incidence of thalidomide-induced peripheral neuropathy among an- kylosing spondylitis patients for 1 year after treatment. In this study, 207 ankylosing spondylitis cases received thalidomide treatment, while 116 ankylosing spondylitis cases received other treat- ments. Results showed that the incidence of thalidomide-induced peripheral neuropathy in the thalidomide group was higher than that in the non-thalidomide group. There was no significant difference in the incidence of neuropathy between the 〈 6 months medication and 〉 6 months medication groups. There were no differences in the mean age, gender, or daily dose between the two groups. The incidence of peripheral neuropathy among patients receiving 25, 50, 75, or 100 mg thalidomide per day was 4.6%, 8.5%, 17.1%, 21.7%, respectively. The incidence was significantly different between the groups receiving 25 mg and 100 mg thalidomide. In conclu- sion, thalidomide can induce peripheral neuropathy within 1 year after treatment of ankylosing spondylitis; however, age and gender have no obvious impact on the incidence of peripheral neuropathy. The incidence of peripheral neuropathy is associated with increasing daily doses of thalidomide.展开更多
观察叶酸与奥美沙坦酯夜间联用对非杓型H型高血压患者患者血压、炎症因子及内皮功能的影响。选取2020年01月至2021年01月本院收治的186例非杓型H型高血压患者为对象,采用奇偶数分组法分为对照组91例和观察组95例。对照组给予奥美沙坦酯...观察叶酸与奥美沙坦酯夜间联用对非杓型H型高血压患者患者血压、炎症因子及内皮功能的影响。选取2020年01月至2021年01月本院收治的186例非杓型H型高血压患者为对象,采用奇偶数分组法分为对照组91例和观察组95例。对照组给予奥美沙坦酯治疗,观察组给予叶酸夜间联合奥美沙坦酯治疗。比较两组动态血压、冠状动脉内皮功能、血清同型半胱氨酸(Hcy)、炎症因子、脉搏波传导速度(PWV)的差异,统计两组安全性、杓型高血压发生率及心血管疾病危险分层情况。两组治疗前动态血压、Hcy、炎症因子、PWV比较,未见统计学差异(P>0.05);与治疗前相比,两组血清Hcy、肿瘤坏死因子-α(TNF-α)、PWV、高敏-C反应蛋白(hs-CRP)及日间、夜间、24 h的收缩压(SBP)和舒张压(DBP)均较前下降,其中观察组治疗后Hcy、炎症因子、PWV及夜间和24 h SBP低于对照组,其他血压状态与对照组比较,未见统计学差异(P>0.05)。两组治疗前冠状动脉内皮功能比较,未见统计学差异(P>0.05);与治疗前相比,两组治疗后前降支中远段峰值血流速度变化率(△V_(LAD))、左主干内径变化率(△D_(LM))均较前下降,且观察组下降更明显(P<0.05)。两组治疗后前降支中远段峰值血流速度(V0_(LAD))、左主干内径(D0_(LM))与治疗前、对照组比较,均未见统计学差异(P>0.05)。观察组杓型高血压发生率为56.84%(54/95)高于对照组的41.76%(38/91),不良反应发生率为9.47%(9/95)与对照组的6.59%(6/91)比较,未见统计学差异(P>0.05)。观察组心血管疾病危险分层优于对照组,有统计学差异(P<0.05)。叶酸与奥美沙坦酯夜间联用可改善非杓型H型高血压患者冠状动脉内皮功能,降低心血管疾病风险,纠正血压昼夜节律,且不增加不良反应。展开更多
基金financially supported by the Natural Science Foundation of Liaoning Province of China,No.2014021081
文摘Thalidomide is an effective drug for the treatment of ankylosing spondylitis but might induce peripheral neuropathy. This major adverse reaction has attracted much concern. The current study aimed to observe the incidence of thalidomide-induced peripheral neuropathy among an- kylosing spondylitis patients for 1 year after treatment. In this study, 207 ankylosing spondylitis cases received thalidomide treatment, while 116 ankylosing spondylitis cases received other treat- ments. Results showed that the incidence of thalidomide-induced peripheral neuropathy in the thalidomide group was higher than that in the non-thalidomide group. There was no significant difference in the incidence of neuropathy between the 〈 6 months medication and 〉 6 months medication groups. There were no differences in the mean age, gender, or daily dose between the two groups. The incidence of peripheral neuropathy among patients receiving 25, 50, 75, or 100 mg thalidomide per day was 4.6%, 8.5%, 17.1%, 21.7%, respectively. The incidence was significantly different between the groups receiving 25 mg and 100 mg thalidomide. In conclu- sion, thalidomide can induce peripheral neuropathy within 1 year after treatment of ankylosing spondylitis; however, age and gender have no obvious impact on the incidence of peripheral neuropathy. The incidence of peripheral neuropathy is associated with increasing daily doses of thalidomide.
文摘观察叶酸与奥美沙坦酯夜间联用对非杓型H型高血压患者患者血压、炎症因子及内皮功能的影响。选取2020年01月至2021年01月本院收治的186例非杓型H型高血压患者为对象,采用奇偶数分组法分为对照组91例和观察组95例。对照组给予奥美沙坦酯治疗,观察组给予叶酸夜间联合奥美沙坦酯治疗。比较两组动态血压、冠状动脉内皮功能、血清同型半胱氨酸(Hcy)、炎症因子、脉搏波传导速度(PWV)的差异,统计两组安全性、杓型高血压发生率及心血管疾病危险分层情况。两组治疗前动态血压、Hcy、炎症因子、PWV比较,未见统计学差异(P>0.05);与治疗前相比,两组血清Hcy、肿瘤坏死因子-α(TNF-α)、PWV、高敏-C反应蛋白(hs-CRP)及日间、夜间、24 h的收缩压(SBP)和舒张压(DBP)均较前下降,其中观察组治疗后Hcy、炎症因子、PWV及夜间和24 h SBP低于对照组,其他血压状态与对照组比较,未见统计学差异(P>0.05)。两组治疗前冠状动脉内皮功能比较,未见统计学差异(P>0.05);与治疗前相比,两组治疗后前降支中远段峰值血流速度变化率(△V_(LAD))、左主干内径变化率(△D_(LM))均较前下降,且观察组下降更明显(P<0.05)。两组治疗后前降支中远段峰值血流速度(V0_(LAD))、左主干内径(D0_(LM))与治疗前、对照组比较,均未见统计学差异(P>0.05)。观察组杓型高血压发生率为56.84%(54/95)高于对照组的41.76%(38/91),不良反应发生率为9.47%(9/95)与对照组的6.59%(6/91)比较,未见统计学差异(P>0.05)。观察组心血管疾病危险分层优于对照组,有统计学差异(P<0.05)。叶酸与奥美沙坦酯夜间联用可改善非杓型H型高血压患者冠状动脉内皮功能,降低心血管疾病风险,纠正血压昼夜节律,且不增加不良反应。
